Annual report pursuant to Section 13 and 15(d)

Patents and Other Intangible Assets - Additional Information (Details)

v3.21.1
Patents and Other Intangible Assets - Additional Information (Details)
12 Months Ended
Dec. 31, 2020
USD ($)
patent
Dec. 31, 2019
USD ($)
Finite-Lived Intangible Assets [Line Items]    
Impairment of intangible assets $ 2,201,000 $ 0
Patent held for sale 156,000 0
Operating loss 8,183,000 5,703,000
Amortization 462,000 454,000
VivoPharm    
Finite-Lived Intangible Assets [Line Items]    
Impairment of intangible assets 2,100,000  
Operating loss $ 1,500,000  
Patents    
Finite-Lived Intangible Assets [Line Items]    
Number of intangible assets impaired | patent 4  
Impairment of intangible assets $ 71,000 $ 0
Allowance for legal fees 50,000  
Patent held for sale $ 156,000  
Software, Customer List and Trade Name | VivoPharm    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, useful life 10 years